Introduction: The effect of once-weekly (OW) subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) analog for the treatment of T2D, has been examined in GLP-1-naïve patients only. Here, we examined glycemic control and weight management in GLP-1-experienced patients switching from another GLP-1 to semaglutide in a real-world setting, using U.S. prescription data.

Methods: Adults (≥18 years old) with T2D were identified in the Explorys (IBM Watson Health) U.S. electronic medical records database (data cut-off 12/5/19). Included patients had ≥1 prescription for semaglutide (index/switch date), a prescription for any other GLP-1 (baseline) in the previous year, and separate HbA1c/weight measurements at 6 or 12 months post-index and in the 90-day pre-index period.

Results: Patients with valid HbA1c (N=365) and weight (N=480) data had similar baseline characteristics. Both the full 6-month cohorts and subgroups with 12-month data had significant HbA1c and weight reductions (Figure). Significant HbA1c improvement at 6 months was sustained at 12 months, whereas weight loss was more pronounced with longer follow-up. HbA1c and weight changes were independent of previous GLP-1 used (p>0.05 between GLP-1s).

Conclusions: Switching to OW semaglutide from another GLP-1 was associated with significant HbA1c and weight reductions in routine clinical practice, independent of previous GLP-1 used.

graphic
View largeDownload slide
Disclosure

I. Lingvay: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., MannKind Corporation, Novo Nordisk A/S, Sanofi, TARGET PharmaSolutions, Valeritas, Inc. Other Relationship; Self; Novo Nordisk A/S. A. Kirk: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. S. Lophaven: Consultant; Self; Novo Nordisk A/S. M.L. Wolden: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J.H. Shubrook: Advisory Panel; Self; Bayer U.S., Eli Lilly and Company, Novo Nordisk Inc., Sanofi US.

Funding

Novo Nordisk A/S

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.